In the last trading session, 4.95 million ImmunityBio Inc (NASDAQ:IBRX) shares changed hands as the company’s beta touched 1.12. With the company’s per share price at $4.14 changed hands at $0.05 or 1.22% during last session, the market valuation stood at $2.76B. IBRX’s last price was a discount, traded about -71.5% off its 52-week high of $7.10. The share price had its 52-week low at $1.21, which suggests the last value was 70.77% up since then. When we look at ImmunityBio Inc’s average trading volume, we note the 10-day average is 5.6 million shares, with the 3-month average coming to 5.15 million.
Analysts gave the ImmunityBio Inc (IBRX) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended IBRX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. ImmunityBio Inc’s EPS for the current quarter is expected to be $InflaRx N.V..
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX was in green as seen at the end of in last trading. With action 33.12%, the performance over the past five days has been green. The jump to weekly highs of 4.30 on Friday, 11/17/23 added 1.22% to the stock’s daily price. The company’s shares are showing year-to-date downside of -18.34%, with the 5-day performance at 33.12% in the green. However, in the 30-day time frame, ImmunityBio Inc (NASDAQ:IBRX) is 229.88% up. Looking at the short shares, we see there were 41.92 million shares sold at short interest cover period of 5.82 days.
The consensus price target for the stock as assigned by Wall Street analysts is $4.00, meaning bulls need a downside of -3.5% from its current market value. According to analyst projections, IBRX’s forecast low is $4.00 with $4.00 as the target high. To hit the forecast high, the stock’s price needs a 3.38% surge from its current level, while the stock would need to tank 3.38% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 2.79%. The 2023 estimates are for ImmunityBio Inc earnings to increase by 10.58%, but the outlook for the next 5-year period is at -1.70% per year.
ImmunityBio Inc is expected to release its next quarterly earnings report on November 08.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 72.58% of ImmunityBio Inc shares while 10.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 38.89%. There are 10.66% institutions holding the ImmunityBio Inc stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 1.55% of the shares, roughly 10.33 million IBRX shares worth $28.73 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 1.42% or 9.5 million shares worth $26.41 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Small-Cap Index Fund and Vanguard Total Stock Market Index Fund. With 2.81 million shares estimated at $7.82 million under it, the former controlled 0.42% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 0.39% of the shares, roughly 2.58 million shares worth around $7.18 million.